36 drugs added to China's insurance list with price cuts | Ombudsman to examine EMA's presubmission meetings | EU OKs bacterial panel from T2 Biosystems
July 20, 2017
DIA Global SmartBrief
News on diagnostic and therapeutic innovations and regulatory science
Top Story
36 drugs added to China's insurance list with price cuts
36 drugs added to China's insurance list with price cuts
(Philippe Huguen/Getty Images)
China's Ministry of Human Resources and Social Security is adding 36 drugs to those covered by basic insurance plans after pharma companies said they would provide an average 44% decrease -- and up to 70% -- from last year's prices. Additions include Celgene's Revlimid; Johnson & Johnson's Zytiga; Roche Holding's Herceptin, Avastin and MabThera; Novartis' Afinitor; Brilinta, from AstraZeneca; and Victoza, from Novo Nordisk.
Reuters (7/19) 
LinkedIn Twitter Facebook Google+ Email
Ombudsman to examine EMA's presubmission meetings
European Ombudsman Emily O'Reilly will investigate whether the meetings of drug companies with officials of the European Medicines Agency before formal submissions influence approval decisions. O'Reilly said such meetings, although valuable, may create "at least some perception of bias" with the public.
In-Pharma Technologist (7/20) 
LinkedIn Twitter Facebook Google+ Email
EU OKs bacterial panel from T2 Biosystems
T2 Biosystems' T2Bacteria Panel has been granted CE mark approval by European regulators. The panel, which will be released in Europe in the third quarter as part of the company's T2Sepsis Solution, operates on the company's T2Dx instrument and takes about 3.5 hours to deliver species-specific results of targeted bacterial infections using whole blood.
GenomeWeb Daily News (free registration) (7/18) 
LinkedIn Twitter Facebook Google+ Email
Trial of Intact Vascular's endovascular system launched in Europe
The first European patient in a study of Intact Vascular's Tack endovascular system, designed for arterial dissection repair, has been enrolled at Austria's Medical University of Graz. The 232-patient, 50-site trial seeks to assess the efficacy and safety of the device in combination with standard balloon angioplasty for the treatment of below-knee critical limb ischemia.
MassDevice (Boston) (7/18) 
LinkedIn Twitter Facebook Google+ Email
Asia Pacific
More R&D will help Indian pharma grow, analysts say
The Indian pharmaceutical sector must increase its R&D investments to meet the challenges of a changing international marketplace, including regulatory oversight by the US FDA, according to a report from S&P Global Ratings. Pricing pressures will encourage a shift to specialty drugs but will also promote the use of generics, the report predicted.
The Economic Times (India)/Press Trust of India (7/17) 
LinkedIn Twitter Facebook Google+ Email
CStone gets China FDA OK to begin cancer drug trial
The China FDA has cleared CStone Pharmaceuticals to start trials of CS1001, including in combination with other therapies, as a treatment for patients with advanced cancers.
BioCentury (7/18) 
LinkedIn Twitter Facebook Google+ Email
North America
HCV drug from Gilead wins FDA approval
Gilead Sciences' single-tablet Vosevi, or sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg, has been approved by the FDA as a treatment for adult patients with chronic hepatitis C virus with genotypes 1 through 6 who had prior treatment with a regimen containing an NS5A inhibitor. The drug is also approved for HCV patients with genotype 1a or 3 who were previously treated with a regimen containing sofosbuvir without an NS5A inhibitor.
Seeking Alpha (free registration) (7/18) 
LinkedIn Twitter Facebook Google+ Email
FDA to update policies to increase generic-drug competition
The FDA intends to issue an internal manual of policies and procedures this year to improve the process for reviewing generic-drug applications and increase competition, according to FDA Commissioner Dr. Scott Gottlieb. The FDA also plans to issue guidance for submitting abbreviated new drug applications suggesting ways to avoid common problems.
Regulatory Focus (7/18) 
LinkedIn Twitter Facebook Google+ Email
Other News
PeptiDream collaborates with Kleo for immuno-oncology drug research
Tokyo-based PeptiDream agreed to work with Kleo Pharmaceuticals on the development of immuno-oncology drugs for multiple indications using PeptiDream's Peptide Discovery Platform System technology to identify peptides against targets selected by Kleo. Under the deal, Kleo will get an upfront payment and retain rights to develop and market products resulting from the agreement, while PeptiDream will receive a tiered portion of the proceeds.
Genetic Engineering & Biotechnology News (7/18) 
LinkedIn Twitter Facebook Google+ Email
DIA News
Mark your calendars! Upcoming DIA events
Want to save even more on registration to conferences and forums, trainings, eLearning and more? Become a DIA member today.
LinkedIn Twitter Facebook Google+ Email
Learn more about DIA:
About DIA | Meetings & Trainings | News & Publications | Membership
Press Releases
Post a Press Release
There is no end. There is no beginning. There is only the infinite passion of life.
Federico Fellini,
film director
LinkedIn Twitter Facebook Google+ Email
Sign Up
SmartBrief offers 200+ newsletters
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Editor  -  Lisa Gough
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2017 SmartBrief, Inc.®
Privacy policy |  Legal Information